Case Report: ITP Treatment After CAR-T Cell Therapy in Patients With Multiple Myeloma

Chimeric antigen receptor T (CAR-T) cell therapy is an attractive strategy for patients with relapsed or refractory hematological malignancies including multiple myeloma (MM). T cells are engineered to attack malignant cells that express tumor-associated antigens and better efficacy could be achieve...

Descripción completa

Detalles Bibliográficos
Autores principales: Du, Mengyi, Huang, Linlin, Kou, Haiming, Li, Chenggong, Hu, Yu, Mei, Heng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9244693/
https://www.ncbi.nlm.nih.gov/pubmed/35784357
http://dx.doi.org/10.3389/fimmu.2022.898341

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9244693/
https://www.ncbi.nlm.nih.gov/pubmed/35784357
http://dx.doi.org/10.3389/fimmu.2022.898341

Ejemplares similares